NextCure to Merge With Privately Held Biotech Avere

Shares of NextCure (NXTC) rose over 200% in premarket trading after announcing a merger with privately held biotech company Avere Therapeutics. The deal includes an $320 million private placement, signaling strong investor interest.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · July 14, 2026, 11:10 UTC

NextCure to Merge With Privately Held Biotech Avere

Tickers: $NXTC

Topics: biotech mergers and acquisitions stock surge

Read the full article at Seeking Alpha

More World news

Nvidia Shares Plunge Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:35 UTC
Jensen Huang Resigns as Nvidia CEO; Colette Kress Appointed Interim CEO TechCrunch · November 12, 2026, 15:37 UTC
Merck KGaA Raises 2026 Outlook Amid Pending Bio-Techne Acquisition Seeking Alpha · November 12, 2026, 15:31 UTC
Chinese AI Firms Seek Alternative Access to Nvidia Chips Amid Potential US Export Restrictions Seeking Alpha · November 12, 2026, 15:32 UTC
Purcell & Lefkowitz LLP Launches Shareholder Investigation into Dick's Sporting Goods PR Newswire · November 12, 2026, 15:34 UTC
Pomerantz Law Firm Investigates Fervo Energy Following Allegations of Securities Fraud PR Newswire · November 12, 2026, 15:35 UTC
Pomerantz Law Firm Investigates Boston Scientific Following Q3 Earnings Miss and Guidance Downgrade PR Newswire · November 12, 2026, 15:35 UTC
Jensen Huang Concludes 33-Year Tenure as CEO of Nvidia Seeking Alpha · November 12, 2026, 15:29 UTC
Metalla Royalty & Streaming Reports Q3 Revenue Growth and Increased Adjusted EBITDA Seeking Alpha · November 12, 2026, 15:26 UTC
Fed Governor Michael Barr Warns AI Market Concentration Could Drive Income Inequality Seeking Alpha · November 12, 2026, 15:27 UTC